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L E T T E R  T O  T H E  E D I T O R
Increased risk donor criteria: The time for change is now
The Public Health Service designation of increased risk donor (IRD) 
was created in 1994 and updated in 2013 to identify donors with 
increased of transmitting HIV, hepatitis B, and hepatitis C. While IRD 
designation was well intentioned, developments since its implemen-
tation	have	created	several	problems.	Advancements	in	testing	and	
treatment have dramatically changed the incidence and trajectory of 
patients with these diseases. The most recent evidence shows that 
IRD organs have equivalent graft and patient survival to non-IRD 
organs, but IRD kidneys are discarded at a 50% higher rate than non-
IRD kidneys. Given nearly 20% of organs are currently labeled as 
IRD, the cumulative result of the IRD designation is hundreds of IRD 
organs, that are safe for transplant and perform as well as non-IRD 
organs, go unused annually. Evidence has shown IRD designation 
creates negative bias among both provider and patients. The Public 
Health Service guidelines are currently in the process of being up-
dated which presents a unique opportunity for the transplant com-
munity to strongly advocate for evidence-based changes which will 
improve access to transplant for all patients. Our letter to the edi-
tor briefly outlines the current problems with the IRD designation 
and proposes recommendations the transplant community should 
endorse.
In an effort to increase the number of life-saving transplants, the 
transplant community must re-evaluate the Public Health Service 
(PHS) designation of increased risk donor (IRD) organs. IRD kidneys 
are discarded at a 50% higher rate than non-IRD kidneys, despite 
equivalent survival.1,2 While the most comprehensive study on IRD 
utilization is dated and should be repeated using recent data, con-
temporary OPTN data show the discard rate of PHS kidneys has 
remained unchanged for over a decade leaving us to believe this 
issue remains unresolved.3 The Department of Health and Human 
Services is currently in the process of updating the PHS guidelines. 
Now is the time to advocate for change that will improve utilization 
of these vital organs.
The PHS guidelines were initially developed in 1994 to identify 
organs with increased risk of transmitting HIV and were revised 
in 2013 to include criteria to identify increased risk of hepatitis B 
and C (HBV and HCV) transmission.4 While the IRD designation 
was well intentioned, developments since their implementation 
have created several problems. The incidence of HIV and the risk 
of transmission has dropped dramatically, new direct-acting antivi-
ral therapies have transformed HCV management, and nucleic acid 
testing	(NAT)	has	significantly	shortened	the	window	period	to	de-
tect infection. The guidelines provide no mechanism to account 
for the highly variable risks associated with specific behaviors. 
This has become increasingly important in the setting of the opioid 
epidemic with nearly 20% of donors currently labeled IRD.5 Most 
importantly, the guidelines clearly create cognitive biases in both 
providers and patients resulting in unequal utilization.6 National 
survey data suggest that transplant surgeons’ perceptions of trans-
mission risk do not correspond with actual risk.7 We believe a good 
proportion of the underutilization stems from the deleterious 
name which results in hundreds of IRD organs that are safe for 




posed 11 recommendations to PHS for guideline improvements.8 
While all 11 recommendations would be an improvement, we believe 
two in particular should be strongly advocated for by the transplant 
community:
1. Reduce the current risk behavior time frame from 12 months 
to 3 months as this is sufficient to detect blood-borne infection 
given modern testing.
2. Change the terminology of “increased risk donor” as this term cre-
ates a negative cognitive bias in both patient and provider. More 
neutral terminology, similar to “extended criteria donor,” would 
allow a reframing of the discussion about risks of disease trans-
mission, treatments if transmission occurs, and the risk of wait-list 
mortality. We suggest the term “PHS criteria donors” but encour-
age a discussion around whatever name is chosen as it has a sig-
nificant effect on utilization.
The forthcoming PHS IRD guideline revision is a unique op-
portunity to impact access to kidney transplantation, and it is vital 
the transplant community strongly advocate for evidence-based 
changes to the guidelines to improve access to transplant for all 
patients.
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